Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review-Reference-Cited by-同舟云学术

Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review

Published:2019-07-11 Issue:2 Volume:4 Page:223-233
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Padmasawitri T. I. Armina,Saragih Sarah Maria,Frederix Gerardus W.,Klungel Olaf^ORCID,Hövels Anke M.

Funder

Indonesian Endowment Fund for Education

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s41669-019-0162-z.pdf

Reference37 articles.

1. Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, EuroScan: the European Information Network on New and Changing Health Technologies, et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. Lancet Glob Health. 2018;6:e1196–252.

2. Packer C, Simpson S, Stevens A. International diffusion of new health technologies: a ten-country analysis of six health technologies. Int J Technol Assess Health Care. 2006;22:419–28.

3. Harrison A, Dixon J, New B, Judge K. Can the NHS cope in future? BMJ. 1997;314:139–42.

4. World Health Organization. HTA Definitions [Internet]. Health Technol. Assess; 2018. https://www.who.int/health-technology-assessment/about/Defining/en/ . Cited 6 Dec 2018.

5. Dankó D. Health technology assessment in middle-income countries: recommendations for a balanced assessment system. J Mark Access Health Policy. 2014. https://doi.org/10.3402/jmahp.v2.23181 .

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis;The Lancet Global Health;2024-06

2. Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2022-10-09